Gerresheimer, a system and solution provider, will present its portfolio of specialised primary packaging solutions, including closures and accessories, as well as drug delivery devices at this year’s CPHI in Frankfurt, Germany, from 28-30th October.
Syngene International, a global contract research, development, and manufacturing organisation (CRDMO), announced site upgrades to accelerate drug discovery and development, helping clients bring novel therapies to market faster.
During a recent visit to ReiThera's facilities, I saw first-hand how the company is leveraging decades of vector expertise, manufacturing capabilities, and a focus on quality to help clients bring gene therapies and vaccines from concept to clinic.
CN Bio, a provider of benchtop Organ-on-a-chip (OOC) solutions that accelerate drug discovery and development, today announced the launch of PhysioMimix Core.
SteriPack, a global contract design and manufacturing organisation (CDMO) for the pharmaceutical and medical device industries, has announced its trading name change to Ensera, signalling a strategic shift in its identity and service offering.
Cold Chain Technologies (CCT) has played a role in demonstrating the viability of ocean freight for high value temperature sensitive pharmaceutical shipments, through a project with logistics companies Kuehne + Nagel and Teva Pharmaceuticals.
On 10th November at 9:00 AM - 9:30 AM CT, Sarang Oka, scientific fellow, Hovione, will do a talk titled "Addressing Practical Challenges in CM via Novel Hardware and Automation" at PharmSci360 in San Antonio, TX.
Orbia Fluor & Energy Materials (Orbia), has announced it has supplied its first large-scale delivery of its new low global warming potential (low-GWP) medical propellant, Zephex 152a.
ACD/Labs, an informatics company that develops and commercialises software in support of R&D, and Covestro have joined forces to bring AI-powered solvent recommendation capabilities to the Percepta platform.
Boyds’ chief development officer, Dr Nick Meyers, and director of regulatory affairs, Dr Eric Hardter, provide advice and guidance to drug developers and sponsors on de-risking the Investigational New Drug (IND) process.
